Erectile Dysfunction References

REFERENCES

Andersson KE. Pharmacology of erectile function and dysfunction. Urol Clin North Am. 2001 May;28(2):233-247. PMID: 11402577
American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem -2003 update. Endocr Pract. 2003 Jan;9(1):77-95. PMID: 12917096
Becher E. Topical alprostadil cream for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2004 Mar;5(3):623-632. PMID: 15013930
Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis for randomized clinical trials [abstract]. J Urol. 1998 Feb;159(2):433-436. PMID: 9649257
Lue TF. Erectile dysfunction. N Engl J Med. 2000 Jun;342(24):1802-1813. PMID: 10853004
Montorsi F, Salonia A, Deho F, et al. Pharmacological management of erectile dysfunction. BJU Int. 2003 Mar;91(5):446-454. PMID: 12603396
Morales A, Heaton JP. Hormonal erectile dysfunction. Evaluation and management. Urol Clin North Am. 2001 May;28(2):279-288. PMID: 11402581
Morgentaler A. Male impotence. Lancet. 1999 Nov;354(9191):1713-1718. PMID: 10568586
MedWormhttp://www.medworm.com/rss/index.php/Endocrinology/15/http://www.medworm.com/rss/medicalfeeds/specialities/Endocrinology.xml
Malaysia Urological Association and MEDACT. Clinical Practice Guide in Erectile Dysfunction. www.acadmed.org.my/view_file.cfm?fileid=211. Aug 2000
American Urological Association Education and Research, Inc. Management of erectile dysfunction [chapter 1 w/ appendix: diagnosis and treatment guideline]. http://www.auanet.org/education/guidelines/erectile-dysfunction.cfm. 2005
British Society for Sexual Medicine. Guidelines on the management of erectile dysfunction. http://www.bssm.org.uk/downloads/BSSM_ED_Management_Guidelines_2009.pdf. 2009
Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 Jun;49(6):822-830. PMID: 9187685
Wespes E, Eardley I, Giuliano F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Association of Urology (EAU). http://www.uroweb.org/gls/pdf/14_Male%20Sexual%20Dysfunction_LR.pdf. 2013 Mar. Accessed 11 Feb 2014.
Hatzimouratidis K, Eardley I, Giuliano F, et al. European Association of Urology guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. 2015 Mar:1-53.
Bella A, Lee J, Carrier S, et al. 2015 Canadian Urological Association practice guidelines for erectile dysfunction. Can Urol Assoc J. 2015 Jan;9(1-2):23-29. doi: 10.5489/cuaj.2699. PMID: 25737750
Alhathal N, Elshal AM, Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: a systematic review. Can Urol Assoc J. 2012 Aug;6(4):269-274. doi: 10.5489/cuaj.11291. PMID: 23093538
Duggin M. Erectile Dysfunction. In: Kellerman R D, Bope E T. Conn's Current Therapy 2018. Philadelphia, PA: Saunders, an imprint of Elsevier, Inc.; 2018. http://dx.doi.org/10.1016/B978-0-323-52769-9.00251-8. Accessed 06 Feb 2018:1068-1070.
Wincze J P. Erectile Dysfunction. In: Ferri F. Ferri's Clinical Advisor 2018. Philadelphia, PA: Elsevier, Inc; 2018. 466-467. :466-467.
Burnett AL, Nehra A, Breau AH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018 Sep;200(3):633-641. doi: 10.1016/j.juro.2018.05.004. PMID: 29746858
Khera, M. Evaluation of male sexual dysfunction. UpToDate. https://www.uptodate.com. 28 Apr 2020.
Khera, M. Treatment of male sexual dysfunction. UpToDate. https://www.uptodate.com . 28 Jul 2021.
Rosen RC, Khera M. Epidemiology and etiologies of male sexual dysfunction . UpToDate. https://www.uptodate.com. 27 May 2021.
Hackett G, Kirby M, Wylie K, et al. British Society for Sexual Medicine Guidelines on the management of erectile dysfunction in men – 2017 . J Sex Med. 2018 Apr;15(4):430-457. doi: 10.1016/j.jsxm.2018.01.023. Accessed 09 Aug 2021. PMID: 29550461

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.